The recent flurry of development activity focused on NASH holds great promise for much needed diagnostics and treatment options, however, commercial success is far from a foregone conclusion. This whitepaper explores future treatment for NASH and a number of major challenges to overcome.
Non-alcoholic Steatohepatitis (NASH) is a condition characterised by excessive fat deposits in the liver, accompanied by inflammation and liver cell damage. In addition, NASH has been associated with increased cardiovascular events independent of its risk factors of type 2 diabetes, obesity and hypertriglyceridemia.
NASH is a complex disease, with poorly understood pathogenesis and natural history of disease, while significant unmet medical needs exist, both for reliable, non-invasive diagnostic procedures as well as effective treatments.